Hennion & Walsh Asset Management Inc. Sells 1,323 Shares of Johnson & Johnson (NYSE:JNJ)

Hennion & Walsh Asset Management Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,325 shares of the company’s stock after selling 1,323 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Johnson & Johnson were worth $5,748,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Tennessee Valley Asset Management Partners grew its stake in shares of Johnson & Johnson by 3.1% during the 4th quarter. Tennessee Valley Asset Management Partners now owns 2,666 shares of the company’s stock worth $418,000 after acquiring an additional 80 shares during the period. Sprucegrove Investment Management Ltd. boosted its position in Johnson & Johnson by 2.4% during the fourth quarter. Sprucegrove Investment Management Ltd. now owns 54,535 shares of the company’s stock worth $8,548,000 after purchasing an additional 1,300 shares during the period. MV Capital Management Inc. increased its stake in shares of Johnson & Johnson by 1.0% in the fourth quarter. MV Capital Management Inc. now owns 17,995 shares of the company’s stock worth $2,821,000 after purchasing an additional 183 shares in the last quarter. WCM Investment Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $248,000. Finally, Louisiana State Employees Retirement System bought a new position in Johnson & Johnson in the 4th quarter worth approximately $22,821,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $159.60 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $384.11 billion, a P/E ratio of 9.95, a PEG ratio of 2.63 and a beta of 0.52. The stock has a 50-day moving average price of $152.63 and a 200-day moving average price of $153.07. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $169.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.80 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.11%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, August 5th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, The Goldman Sachs Group cut their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.